Human telomerase inhibition and cytotoxicity of regioisomeric disubstituted amidoanthraquinones and aminoanthraquinones

被引:34
作者
Huang, HS [1 ]
Chou, CL
Guo, CL
Yuan, CL
Lu, YC
Shieh, FY
Lin, JJ
机构
[1] Natl Def Med Ctr, Sch Pharm, Taipei 114, Taiwan
[2] Natl Yang Ming Univ, Inst Biopharmaceut Sci, Taipei 112, Taiwan
关键词
telomerase; cytotoxicity; amidoanthraquinones; aminoanthraquinones; hTERT;
D O I
10.1016/j.bmc.2004.12.036
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Telomerase is an attractive target for the rational design of new anticancer drugs due to its central role in the control of cellular proliferation. A number of 1,4-disubstituted amidoanthraquinones and 1,5-disubstituted aminoanthraquinones that are related to mitoxantrone and ametantrone have previously been prepared. The present study details the effects on human telomerase of these new classes of 1,4- and 1,5-difunctionalized tricyclic anthraquinone compounds. We have used cytotoxicity assay, reporter SEAP assay to monitor the hTERT expression, and TRAP-G4 assay to measure the relative activity of these compounds, and have examined how the attached substituents affect their ability to influence telomerase. Cytotoxicity levels in human tumor cell lines were at comparable levels for several compounds. Structural and activity relationships indicated that the position of disubstituent side chains is important for its inhibitory effect. Moreover, a primary amine or tertiary amine on the substitution group appears to be required for the telomerase inhibitory effect. There is no significant correlation between telomerase activity and cytotoxicity. These symmetrical disubstituted anthraquinones may represent useful leads for the development of human telomerase inhibitors as potential anticancer agents, and the exact mode of intercalative binding is dictated by the positional placement of substituent side chains for effective telomerase inhibition. (C) 2005 Published by Elsevier Ltd.
引用
收藏
页码:1435 / 1444
页数:10
相关论文
共 73 条
  • [1] Cytostatic concentrations of anticancer agents do not affect telomerase activity of leukaemic cells in vitro
    Akiyama, M
    Horiguchi-Yamada, J
    Saito, S
    Hoshi, Y
    Yamada, O
    Mizoguchi, H
    Yamada, H
    [J]. EUROPEAN JOURNAL OF CANCER, 1999, 35 (02) : 309 - 315
  • [2] Akiyama Masaharu, 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P567, DOI 10.2174/1568011023353778
  • [3] Asai A, 2003, CANCER RES, V63, P3931
  • [4] BASRA J, 1985, ANTI-CANCER DRUG DES, V1, P45
  • [5] Blackburn E, 1999, MT SINAI J MED, V66, P292
  • [6] Extension of life-span by introduction of telomerase into normal human cells
    Bodnar, AG
    Ouellette, M
    Frolkis, M
    Holt, SE
    Chiu, CP
    Morin, GB
    Harley, CB
    Shay, JW
    Lichtsteiner, S
    Wright, WE
    [J]. SCIENCE, 1998, 279 (5349) : 349 - 352
  • [7] Boitte N, 1997, ANTI-CANCER DRUG DES, V12, P481
  • [8] BURKE TG, 1988, CANCER CHEMOTH PHARM, V21, P274
  • [9] Design of telomerase inhibitors for the treatment of cancer
    Cairns, D
    Anderson, RJ
    Perry, PJ
    Jenkins, TC
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2002, 8 (27) : 2491 - 2504
  • [10] Cerezo A, 2002, J CELL SCI, V115, P1305